Condition
Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type clinical trials that are recruiting, at sites in 2 countries (most in United States (2), Mexico (1)). By phase: Phase 3 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Ruxolitinib with CHOP for untreated nodal TFH cell lymphoma
This phase 1 trial tests whether adding ruxolitinib to CHOP chemotherapy is safe and tolerable in adults with untreated nodal TFH cell lymphoma.
-
High-dose chemotherapy with autologous stem cell transplant versus observation for peripheral T‑cell lymphoma in complete remission
This trial tests whether giving high‑dose chemotherapy followed by the patient's own stem cell transplant helps adults with peripheral T‑cell lymphoma who are in complete remission stay cancer‑free longer than observation alone.
Related topics
Quick answers
How many Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (2 trials), Mexico (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.